This study is in progress, not accepting new patients

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

a study on Parkinson's Disease Multiple System Atrophy

Summary

Eligibility
for people ages 35-75 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around

Description

Summary

The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.

Official Title

A Pre-Gene Therapy Study of Early Parkinson's or Multiple System Atrophy Progression by Longitudinal Clinical and Biomarker Assessments

Keywords

Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy, MSA, MSA-P, PD, Observational, Natural History, Parkinson Disease, Shy-Drager Syndrome, Atrophy

Eligibility

You can join if…

Open to people ages 35-75

  • Diagnosis of Idiopathic PD
  • Diagnosis of MSA-P
  • One to six years from clinical diagnosis of PD
  • Less than 4 years from clinical diagnosis of MSA with expected survival >3 years
  • Stable medication regimen
  • Ability to walk with or without an assistive device

You CAN'T join if...

  • Movement disorder due to known cerebrovascular disease, brain tumor, trauma, exposure to parkinsonian-linked toxicants or other neurological diseases
  • Presence of dementia, psychosis, substance abuse or poorly controlled depression
  • Prior brain surgery (i.e. deep brain stimulation) or other brain imaging abnormalities
  • History of cancer or poorly controlled medical conditions
  • Receiving an investigational drug

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Locations

  • University of California Irvine
    Irvine California 92697 United States
  • OHSU Parkinson Center & Movement Disorders Program
    Portland Oregon 97239 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Asklepios Biopharmaceutical, Inc.
ID
NCT05699460
Study Type
Observational
Participants
Expecting 150 study participants
Last Updated